

## Screened selection design for randomised phase II oncology trials : an example in chronic lymphocytic leukaemia

Yap, Christina; Billingham, Lucinda; Pettitt, Andrew

DOI:

[10.1186/1745-6215-12-S1-A91](https://doi.org/10.1186/1745-6215-12-S1-A91)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Yap, C, Billingham, L & Pettitt, A 2011, 'Screened selection design for randomised phase II oncology trials : an example in chronic lymphocytic leukaemia', *Trials*, vol. 12, no. Suppl 1, A91. <https://doi.org/10.1186/1745-6215-12-S1-A91>

[Link to publication on Research at Birmingham portal](#)

### Publisher Rights Statement:

Eligibility for repository : checked 03/04/2014

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**ORAL PRESENTATION****Open Access**

# Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia

Christina Yap<sup>1\*</sup>, Lucinda Billingham<sup>1,2</sup>, Andrew Pettitt<sup>3</sup>

From Clinical Trials Methodology Conference 2011  
Bristol, UK. 4-5 October 2011

## Background

There is a growing number of potential new treatment regimens for chronic lymphocytic leukaemia (CLL). As there is limited number of patients, it is important that statistical methodologies in Phase II trials efficiently select promising regimens for subsequent evaluation in a confirmatory, larger-scale Phase III trial.

## Methods

In this study, we propose the screened selection design, which combines two conventional Phase II trial designs to provide a practical multi-stage approach for evaluating the efficacy of two experimental arms in high-risk CLL patients. Our aim is to select the most promising regimen in terms of effectiveness to be recommended for further testing. The proposed Phase II randomised design is divided into two different segments. In the first segment, patients are randomised equally into two experimental arms. By applying Simon's two-stage design [1] in each of the two parallel experimental arms, this allows for initial determination of efficacy and early stopping for futility in any of the arms. If there are an insufficient number of responses in the first stage, recruitment will not continue for that particular arm. Otherwise, the study proceeds to stage 2 to randomize further patients to each arm. The second segment of the study involves the play-the-winner selection strategy as proposed by Simon, Wittes and Ellenberg [2], which only applies if results from both arms are found to be positive. Our proposed design allows the treatment arm with the

highest response rates to be recommended only if the efficacy rate is greater than a specified clinically-relevant value. The number of subjects required for each treatment arm in the first segment is selected to be as close as possible to the number required for the selection strategy in the second segment according to pre-specified error rates. The operating characteristics of the trial design are explored via a simulation study.

## Results

The proposed approach has the advantage of substantial reduction in the probability of incorrectly selecting an ineffective arm whose rates are not clinically significant or when no true difference exists between the arms. The only compromise is a slight reduction in the probability of correctly selecting an effective treatment arm if one exists. This approach is comparable to the Bayesian Selection Strategy proposed by Estey and Thall [3].

## Conclusions

The proposed approach provides an easy to implement Phase II design to select an effective and most promising treatment regimen for further testing in Phase III.

## Author details

<sup>1</sup>MRC Midland Hub for Trials Methodology Research, University of Birmingham, Birmingham, B15 2TT, UK. <sup>2</sup>Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK. <sup>3</sup>Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, L69 3GA, UK.

Published: 13 December 2011

## References

1. Simon R: Optimal two-stage designs for Phase II. *Clinical Trials* 1989, **10**:1-10.

\* Correspondence: c.yap@bham.ac.uk

<sup>1</sup>MRC Midland Hub for Trials Methodology Research, University of Birmingham, Birmingham, B15 2TT, UK

Full list of author information is available at the end of the article

2. Simon R, Witten RE, Ellenberg SS: Randomized phase II clinical trials. *Cancer Treat Rep* 1985, **69**:1375-1381.
3. Estey E, Thall PF: New designs for phase II clinical trials. *Blood* 2003, **102**:442-448.

doi:10.1186/1745-6215-12-S1-A91

**Cite this article as:** Yap et al.: Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia. *Trials* 2011 12(Suppl 1):A91.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

